Patents by Inventor Keehoon Jung

Keehoon Jung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11279765
    Abstract: Agents that inhibit CX3CL1 in endothelial cells to reduce or inhibit immunosuppression mechanisms that are co-opted by cancer cells to evade host immune system, and that reduce immunosuppression in context of therapies that target VEGF-dependent signaling, and methods of use thereof.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: March 22, 2022
    Assignee: The General Hospital Corporation
    Inventors: Dai Fukumura, Keehoon Jung, Rakesh K. Jain
  • Publication number: 20200216549
    Abstract: Agents that inhibit CX3CL1 in endothelial cells to reduce or inhibit immunosuppression mechanisms that are co-opted by cancer cells to evade host immune system, and that reduce immunosuppression in context of therapies that target VEGF-dependent signaling, and methods of use thereof.
    Type: Application
    Filed: July 9, 2018
    Publication date: July 9, 2020
    Inventors: Dai Fukumura, Keehoon Jung, Rakesh K. Jain
  • Patent number: 10259860
    Abstract: The present application discloses an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and Angiopoietin polypeptide, which includes a nucleotide sequence encoding a Tie2 component and a VEGFR component.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: April 16, 2019
    Assignee: APROGEN INC.
    Inventors: Hak-Zoo Kim, Young Jun Koh, Ho-Min Kim, Keehoon Jung, Choonjoo Jeon, Gou Young Koh
  • Publication number: 20150183864
    Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.
    Type: Application
    Filed: November 12, 2014
    Publication date: July 2, 2015
    Inventors: KEEHOON JUNG, YOUNG JUN KOH, GYUN MIN LEE, SUN CHANG KIM, GOU YOUNG KOH
  • Patent number: 8927232
    Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: January 6, 2015
    Assignee: Korea Advanced Institute of Science and Technology (KAIST)
    Inventors: Keehoon Jung, Young Jun Koh, Gyun Min Lee, Sun Chang Kim, Gou Young Koh
  • Publication number: 20100150926
    Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.
    Type: Application
    Filed: December 11, 2009
    Publication date: June 17, 2010
    Inventors: Keehoon JUNG, Young Jun Koh, Gyun Min Lee, Sun Chang Kim, Gou Young Koh
  • Publication number: 20090312249
    Abstract: The present application discloses a nucleic acid molecule encoding a fusion polypeptide capable of binding myeloid differentiation protein-2 (MD-2) polypeptide, which includes: a nucleotide sequence encoding an MD-2 polypeptide-binding portion of human toll-like receptor 4 (TLR4), a leucine-rich repeats (LRR) module, and a multimerizing component.
    Type: Application
    Filed: December 8, 2008
    Publication date: December 17, 2009
    Inventors: Keehoon Jung, HoMin Kim, Hak-Zoo Kim, Jung-Eun Lee, Gyun Min Lee, Sun Chang Kim, Jie-Oh Lee, Hak-Sung Kim, Gou Young Koh
  • Publication number: 20080242587
    Abstract: The present application discloses an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and Angiopoietin polypeptide, which includes a nucleotide sequence encoding a Tie2 component and a VEGFR component.
    Type: Application
    Filed: October 31, 2007
    Publication date: October 2, 2008
    Inventors: Hak-Zoo Kim, Young Jun Koh, Ho-Min Kim, Keehoon Jung, Choonjoo Jeon, Gou Young Koh